ischemic cerebrovascular stroke. Cerebral infarction due to embolism of cerebral arteries
Conditions
Interventions
Intervention 1: Tablet Iranian Clopidegrol made by Exir Co. 75 mg daily for 1 month as the case group, one per day. Intervention 2: Tablet Plavix (75 mg) per os (orally) daily were used for control gr
Treatment - Drugs
Tablet Iranian Clopidegrol made by Exir Co. 75 mg daily for 1 month as the case group, one per day
Tablet Plavix (75 mg) per os (orally) daily were used for control group for one month, one per day
Sponsors
Baqiyatallah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: [Inclusion criteria]: Patients with Ischemic Heart Disease or ischemia; Patients consent for taking part in study; Patient cooperation in experiment pursuit and taking drugs; Patients shouldn’t be participating in any other clinical trial; Not having any drug taking record in the last month, [Exclusion criteria]: Existence of any hemorrhagic diseases, for instance peptic ulcer and inner-cranial hemorrhage; Existence of accompanied diseases interfering with drugs taken; Any record of allergy to Palvix or Clopidex; Any contraindications for taking Palvix or Clopidex. (Thrombocytopenia, liver disorders, Neutropenia-…); Those of patients who needed some mechanical hemodynamic support like using balloon pump; age more than 85 years and under 18 years.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coagulation profile. Timepoint: baseline and one month later. Method of measurement: using platelet count, bleeding time and coagulation time. | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet aggrigation. Timepoint: baseline and one month later. Method of measurement: aggrigometery test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Majid Shohrati
Baqiayatallah University of Medical Sciences, Chemial Injuries Research Center
Outcome results
None listed